The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Clinical Therapeutics
PreviousPrevious
Volume 355:704-712 August 17, 2006 Number 7
NextNext

Tumor Necrosis Factor Inhibitors for Rheumatoid Arthritis
D.L. Scott, M.D., and G.H. Kingsley, M.B., Ch.B., Ph.D.

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-PowerPoint Slide Set
-Purchase this article

Commentary
-Letters

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-PubMed Citation

This Journal feature begins with a case vignette that includes a therapeutic recommendation. A discussion of the clinical problem and the mechanism of benefit of this form of therapy follows. Major clinical studies, the clinical use of this therapy, and potential adverse effects are reviewed. Relevant formal guidelines, if they exist, are presented. The article ends with the authors' clinical recommendations.

Rheumatoid arthritis developed in a 25-year-old woman, who was found to have a positive rheumatoid factor (150 IU per milliliter); she had no periarticular radiologic erosions or extraarticular disease. Oral methotrexate was started and incrementally increased to 20 mg . . . [Full Text of this Article]

The Clinical Problem

Pathophysiology and Effect of Therapy

Clinical Evidence

Clinical Use

Adverse Effects

Areas of Uncertainty

Guidelines

Recommendations


Source Information

From the Department of Rheumatology, Kings College London School of Medicine, Weston Education Centre, Kings College (D.L.S., G.H.K.); the Department of Rheumatology, Kings College Hospital (D.L.S.); and the Department of Rheumatology, University Hospital Lewisham (G.H.K.) — all in London.


Related Letters:

Tumor Necrosis Factor Inhibitors for Rheumatoid Arthritis
Roos J. C., Ostor A. J., Okamoto H., Dentener M. A., Wouters E. F.M., Scott D.L., Kingsley G.H.
Extract | Full Text | PDF  
N Engl J Med 2006; 355:2046-2048, Nov 9, 2006. Correspondence

This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.